An Alport syndrome genetic test examines COL4A3, COL4A4, and COL4A5, the genes that encode part of the type IV collagen network in the kidney’s filtering membrane, inner ear, and eye. A pathogenic result can explain persistent blood in the urine, proteinuria, progressive kidney disease, sensorineural hearing loss, or characteristic eye findings. It also establishes whether the condition is X-linked, autosomal recessive, autosomal dominant, or occasionally more complex, which changes risks for relatives and future children. Modern testing usually analyzes all three genes together because the clinical features overlap and because the same initial finding—microscopic hematuria—can occur in several inheritance patterns. A positive result may support earlier kidney-protective treatment and targeted family testing before symptoms become obvious. A negative result does not fully exclude Alport syndrome if the assay misses a structural, deep intronic, mosaic, or otherwise hard-to-detect variant. Results should be reviewed with kidney findings, family history, hearing and eye assessments, and the laboratory’s stated test coverage.
- Persistent microscopic blood in the urine is the most common early clue, often appearing years before kidney function declines.
- COL4A5 variants usually cause X-linked Alport syndrome, while COL4A3 or COL4A4 variants can cause autosomal recessive or autosomal dominant disease.
- A pathogenic or likely pathogenic result can establish the molecular diagnosis when it fits the kidney, hearing, eye, and family findings.
- A heterozygous COL4A3 or COL4A4 result is not always “benign thin basement membrane disease”; some carriers develop proteinuria, chronic kidney disease, or kidney failure.
- A VUS does not confirm Alport syndrome and should not be used alone for predictive testing or irreversible decisions.
- First-degree relatives may need targeted testing and urine screening, even when they feel well and have normal kidney function.
Table of Contents
- How COL4A3, COL4A4, and COL4A5 cause disease
- Clinical reasons to order testing
- Laboratory approach and sample requirements
- Positive, negative, and uncertain results
- Inheritance patterns and family risk
- What the genotype may mean for prognosis and treatment
- How genetic testing fits with biopsy and clinical tests
- Actions after testing
How COL4A3, COL4A4, and COL4A5 cause disease
The glomerular basement membrane is part of the kidney filter that keeps blood cells and large proteins in the bloodstream while allowing waste and water to pass into urine. Its mature collagen network contains alpha-3, alpha-4, and alpha-5 chains of type IV collagen. COL4A3, COL4A4, and COL4A5 provide the instructions for those chains.
A disease-causing variant can disrupt assembly, stability, or function of the collagen network. The basement membrane may begin unusually thin and later become irregular, split, and layered. Blood leaks into the urine, then protein leakage and scarring can develop over time. The same collagen network contributes to structures in the cochlea and eye, explaining why some people develop high-frequency sensorineural hearing loss, anterior lenticonus, retinal flecks, corneal problems, or other ocular findings.
The gene and number of altered copies shape the inheritance pattern:
- COL4A5: located on the X chromosome; one pathogenic variant causes X-linked Alport syndrome.
- COL4A3 or COL4A4, two pathogenic variants: usually cause autosomal recessive Alport syndrome.
- COL4A3 or COL4A4, one pathogenic variant: can cause autosomal dominant Alport syndrome or a milder collagen IV–related kidney phenotype.
- Variants in more than one collagen IV gene: rare digenic combinations can modify severity and inheritance.
Older labels such as “benign familial hematuria” and “thin basement membrane nephropathy” can understate long-term risk in some heterozygous COL4A3 or COL4A4 carriers. Many remain stable, but others develop proteinuria, hypertension, reduced kidney function, focal segmental glomerulosclerosis, or kidney failure. The result should therefore be described by gene, variant, inheritance, and clinical findings rather than by a reassuring label alone.
A collagen missense variant that replaces glycine in the triple-helical region is a common disease mechanism, but not every glycine change is automatically pathogenic. Truncating, splice, deletion, duplication, and other variant types also occur. Clinical laboratories apply formal variant classification criteria and gene-specific evidence.
Clinical reasons to order testing
Genetic testing should be considered when a person has persistent glomerular hematuria, especially when it is accompanied by a family history, proteinuria, hearing loss, or unexplained chronic kidney disease. “Glomerular” means the blood is thought to come from the kidney filter rather than a urinary infection, stone, tumor, or another urologic source.
Common indications include:
- Persistent microscopic hematuria without an acquired explanation
- Recurrent visible blood in the urine, particularly from childhood
- Hematuria plus proteinuria, hypertension, or declining estimated glomerular filtration rate
- A family history of hematuria, kidney failure, dialysis, kidney transplant, or unexplained hearing loss
- Sensorineural hearing loss with kidney findings
- Anterior lenticonus or another characteristic ocular sign
- A kidney biopsy showing a thin, irregular, split, or lamellated glomerular basement membrane
- Focal segmental glomerulosclerosis or steroid-resistant nephrotic syndrome with suspected inherited disease
- A known familial COL4A3, COL4A4, or COL4A5 variant
- Potential kidney donation by a relative from an affected family
Testing all three genes together is generally more efficient than assuming an inheritance pattern from sex or family history. Small families, de novo variants, adoption, incomplete records, variable expression, and later-onset disease can make a pedigree misleading. A woman with COL4A5-related disease may have significant kidney risk, and a man with a heterozygous COL4A3 variant may also develop progressive disease.
Genetic testing can be especially useful before kidney biopsy in a child or young adult with a strong Alport pattern. A clear pathogenic result may avoid an invasive procedure, although biopsy still has value when another kidney disease may coexist or when the genetic result is negative or uncertain.
A broader kidney disease panel or exome analysis may be preferable when the phenotype includes nephrotic syndrome, cysts, congenital anomalies, metabolic features, or another pattern not typical of Alport syndrome. A multigene panel can evaluate collagen IV genes alongside other hereditary nephropathy genes, but it also raises the chance of uncertain or incidental findings.
Laboratory approach and sample requirements
Most tests use DNA from blood, saliva, or a cheek swab. Blood is often preferred when high-quality DNA or copy-number analysis is needed. Fasting is not required, and ordinary medicines do not change the inherited sequence.
A comprehensive assay typically includes sequence analysis of COL4A3, COL4A4, and COL4A5 plus deletion and duplication analysis. Next-generation sequencing detects many single-nucleotide changes and small insertions or deletions. Copy-number methods can identify whole-exon or multiexon losses and gains that sequencing alone may miss.
The laboratory report should state whether the test covers:
- All coding exons and nearby splice junctions
- Exon-level deletions and duplications
- The COL4A5-COL4A6 region, where larger deletions can be associated with diffuse leiomyomatosis
- Mitochondrial or other kidney genes if a panel was ordered
- Mosaic variants at low allele fractions
- Deep intronic, promoter, or other noncoding regions
Standard panels may not detect every deep intronic variant, balanced rearrangement, low-level mosaic change, or complex structural variant. Genome sequencing, RNA studies, long-read methods, or research testing may be considered when clinical suspicion remains high after a negative result.
Testing a relative for a known familial variant is simpler and is often called targeted or cascade testing. The family member’s original report should be sent to the laboratory so the exact variant and transcript are matched. A targeted familial variant test should not be substituted with a generic screening panel that may omit the relevant region.
Turnaround time is commonly several weeks, though targeted family testing may be faster. Kidney transplantation, blood transfusion, and dialysis do not usually change germline DNA results. A recent bone-marrow or stem-cell transplant can make blood DNA donor-derived, so the laboratory may need cultured skin cells or another nonhematologic sample.
Before testing, patients should understand that the result can reveal risk in relatives and reproductive implications. It may also clarify that someone previously considered only a “carrier” has their own need for kidney surveillance. Genetic counseling is particularly useful when the family includes potential kidney donors, minors, or reproductive planning.
Positive, negative, and uncertain results
The most informative report links the variant to a specific inheritance pattern and explains whether the finding is diagnostic, carrier-related, uncertain, or unlikely to account for the phenotype.
Pathogenic or likely pathogenic result
A pathogenic or likely pathogenic COL4A5 variant in a person with compatible findings establishes X-linked Alport syndrome. A pathogenic variant in both copies of COL4A3 or COL4A4 establishes autosomal recessive disease when the variants are confirmed to be on opposite chromosomes. One pathogenic COL4A3 or COL4A4 variant supports autosomal dominant Alport syndrome or a related collagen IV nephropathy, but severity can vary widely.
“Likely pathogenic” is clinically actionable in the same general way as “pathogenic” when the phenotype fits. The report may recommend testing parents or other relatives to confirm phase, determine whether the variant is inherited or de novo, and refine risk.
Negative result
A negative result means the assay did not identify a reportable cause; it does not prove that the collagen IV network is normal. The possibility of Alport syndrome remains if the clinical and biopsy findings are strong. Reasons include limited coverage, a difficult structural variant, low-level mosaicism, a deep intronic change, a variant not yet recognized as disease-causing, or a different gene.
The next step may be reanalysis, a broader kidney panel, genome sequencing, RNA analysis, or kidney biopsy. Repeating the same test without expanding the method rarely adds value unless there was a sample-quality concern.
Variant of uncertain significance
A VUS lacks enough evidence to be classified as harmful or harmless. It should not be used alone to diagnose an unaffected relative, exclude someone from kidney donation, determine prenatal status, or start lifelong treatment. Supporting data can include urine findings, biopsy pattern, hearing and eye features, segregation with disease in relatives, population frequency, location in the collagen domain, and laboratory functional evidence.
Testing a clearly affected and an older unaffected relative can sometimes help, but family segregation does not automatically settle the classification. Laboratories may reclassify a VUS as evidence accumulates. Patients should keep contact information current and ask whether periodic reanalysis is available.
One variant when two are expected
A person with a severe autosomal recessive phenotype may have only one COL4A3 or COL4A4 pathogenic variant detected. This can mean the second variant lies outside routine coverage, is structural, or remains unrecognized. It may also mean the phenotype has another cause. Additional methods and parental testing can clarify whether the finding is sufficient.
Inheritance patterns and family risk
Family risk is calculated from the gene, the affected person’s sex chromosomes, the number of variants, and the partner’s status.
| Genetic form | Who may inherit the variant | General risk pattern |
|---|---|---|
| X-linked, COL4A5 variant in a father | All daughters, no sons | Daughters inherit his X chromosome; sons inherit his Y chromosome |
| X-linked, COL4A5 variant in a mother | Sons and daughters | Each child has a 50% chance of inheriting the variant |
| Autosomal dominant, one COL4A3 or COL4A4 variant | All sexes | Each child has a 50% chance of inheriting the variant |
| Autosomal recessive, two COL4A3 or COL4A4 variants | Depends on partner status | Children are at disease risk when the partner carries a pathogenic variant in the same gene |
A woman with a COL4A5 pathogenic variant should not be described as an unaffected carrier by default. X-chromosome inactivation creates variable expression, and some women develop proteinuria, hearing loss, chronic kidney disease, or kidney failure. They need their own surveillance.
A person with one COL4A3 or COL4A4 pathogenic variant may have autosomal dominant disease and may also be a carrier for autosomal recessive disease. If a reproductive partner carries a pathogenic variant in the same gene, a child could inherit two variants and have more severe autosomal recessive Alport syndrome. Partner testing may therefore be considered before pregnancy.
For a couple in which both partners carry pathogenic variants in the same autosomal gene, each pregnancy generally has a 25% chance of biallelic disease, a 50% chance of a child with one variant, and a 25% chance of inheriting neither familial variant. Variant-specific severity may differ, and phase must be confirmed.
Prenatal diagnosis and preimplantation genetic testing are possible when familial variants are known. These choices are personal. Genetic counseling should explain the range of kidney, hearing, and eye outcomes without assuming that testing must be used to avoid an affected pregnancy.
What the genotype may mean for prognosis and treatment
A molecular diagnosis can guide risk assessment, but it does not provide an exact kidney-failure date. Sex, inheritance pattern, variant type, family course, proteinuria, blood pressure, treatment timing, and other kidney stressors all contribute.
Males with X-linked COL4A5 disease and people of any sex with autosomal recessive disease generally have the highest risk of early progression. Large deletions, nonsense variants, frameshift variants, and some splice variants often disrupt collagen more completely and may be associated with earlier kidney failure than some missense variants. These are population-level trends, not guarantees for an individual.
Heterozygous COL4A3 or COL4A4 carriers usually have a lower average risk than classic X-linked males or autosomal recessive patients, yet the range is broad. Proteinuria, hypertension, reduced estimated GFR, and a family history of kidney failure signal greater concern.
Early blockade of the renin-angiotensin system with an ACE inhibitor or angiotensin receptor blocker can slow progression. Treatment recommendations depend on genotype, age, albumin or protein leakage, blood pressure, pregnancy status, and current guidelines. A genetic result may justify closer monitoring and earlier nephrology involvement before the person feels ill.
The test does not measure current kidney damage. Urine albumin-to-creatinine ratio, serum creatinine, estimated GFR, blood pressure, and trend over time remain essential. Hearing tests can detect high-frequency loss before it affects conversation. Eye examination may identify characteristic findings, but a normal eye exam does not exclude Alport syndrome.
A pathogenic result also affects living kidney donation. A relative carrying the familial variant may face their own lifetime kidney risk and is generally not an ideal donor without expert evaluation. A negative targeted result can be reassuring only when the family’s pathogenic variant is clearly established and the relative truly tested negative for it.
How genetic testing fits with biopsy and clinical tests
Genetic testing and kidney biopsy answer related but different questions. DNA identifies an inherited cause; biopsy shows the structure and current tissue pattern. Electron microscopy in Alport syndrome may reveal thinning, irregular thickening, splitting, lamellation, and a basket-weave appearance of the glomerular basement membrane. Collagen IV immunostaining can show abnormal alpha-chain expression in some cases.
A biopsy may be unnecessary when the phenotype and genetic result are definitive. It remains useful when:
- The genetic result is negative or uncertain
- Proteinuria or kidney decline is more severe than expected
- An immune, metabolic, or other glomerular disease may coexist
- Treatment depends on distinguishing Alport syndrome from another diagnosis
- The laboratory found a variant whose clinical relevance is unclear
Urinalysis should be repeated rather than relying on one sample. Exercise, fever, menstruation, infection, stones, and contamination can cause transient blood. Persistent glomerular hematuria with dysmorphic red cells or casts is more concerning. Protein or albumin measurement provides prognostic information beyond a dipstick.
Audiology and ophthalmology are supportive, not screening substitutes for DNA. Hearing loss in Alport syndrome is usually not congenital and may emerge in late childhood or adulthood depending on the form. Eye findings are more frequent in severe X-linked males and autosomal recessive disease, but many genetically confirmed individuals have none.
Family records can be highly informative. Ages at proteinuria, kidney failure, dialysis, transplant, hearing-aid use, and diagnosis help estimate the family’s course. However, improved treatment means a younger relative’s outcome may be better than that of an older untreated family member.
When records are incomplete, obtaining death certificates, transplant summaries, audiograms, or old biopsy reports can sharpen interpretation. Even a relative described only as having “kidney trouble” may provide a useful clue if the age of onset and treatment history are known.
Actions after testing
After a pathogenic result, the immediate priority is not repeating the gene test; it is establishing a surveillance and treatment plan. Typical steps include:
- Review the report with nephrology or a genetics professional and confirm the inheritance pattern.
- Measure blood pressure, serum creatinine, estimated GFR, and urine albumin or protein.
- Discuss when to begin or optimize ACE-inhibitor or ARB therapy.
- Arrange baseline and periodic hearing assessment based on age and genetic form.
- Obtain an eye examination when clinically indicated, especially in higher-risk forms.
- Offer targeted testing and urinalysis to first-degree relatives.
- Review reproductive risks and partner testing when relevant.
- Avoid unnecessary exposure to kidney-toxic medicines and address smoking, obesity, diabetes, and other kidney risks.
After a negative result, ask whether all three genes and deletion/duplication analysis were included. If suspicion remains high, discuss biopsy, broader sequencing, genome testing, or reanalysis rather than assuming the condition is excluded.
After a VUS, base care on the person’s actual kidney findings. Hematuria and proteinuria still deserve management even when the DNA answer is unresolved. Do not test healthy relatives for predictive purposes unless a genetics professional believes segregation could materially clarify the classification.
Seek urgent care for visible blood in urine with clots or inability to urinate, rapidly worsening swelling, severe shortness of breath, very high blood pressure with symptoms, or signs of acute kidney injury. Most Alport progression is gradual, but new severe symptoms require prompt evaluation rather than waiting for a genetics appointment.
References
- Alport Syndrome 2025 (Review)
- Guidelines for Genetic Testing and Management of Alport Syndrome 2022 (Guideline)
- Diagnosis, management and treatment of the Alport syndrome – 2024 guideline on behalf of ERKNet, ERA and ESPN 2025 (Guideline)
- Alport Syndrome: Clinical Utility of Early Genetic Diagnosis in Children 2024 (Review)
- A comprehensive review of Alport syndrome 2024 (Review)
- The Phenotypic Spectrum of COL4A3 Heterozygotes 2023 (Review)
Disclaimer
This article is for education and does not diagnose Alport syndrome or interpret a specific COL4A3, COL4A4, or COL4A5 report. Kidney treatment, family testing, donor evaluation, and reproductive decisions should be guided by nephrology and genetics professionals using the exact variant and clinical findings. Seek urgent care for severe swelling, breathing difficulty, a marked drop in urine output, or symptoms of dangerously high blood pressure.
